1. Vulvar and vaginal neoplasia in women with inflammatory bowel disease
- Author
-
Rouvroye, M.D., Tack, G.J., Mom, C.H., Lissenberg-Witte, B.I., Pierik, M.J., Neefjes-Borst, E.A., Boer, N.K.H. de, Lowenberg, M., Bodelier, A., Verbeek, W.H., Schoon, E., Witteman, E.M., Herwaarden, M.A., Woude, C.J. van der, Lutgens, M., Kouw, E., Veek, P.J. van der, Hulst, R.W. van der, Sipkema, H., Nissen, L.H.C., Bus, P.J., Meulen, A.E. van der, Bruijne, F.H. de, Waaij, L.A. van der, Noomen, C.G., Jharap, B., Schmittgens, S., Jansen, J.M., Hoentjen, F., Lammertink, M.H.A., Houben, G.M.P., Minderhoud, I.M., Dijkstra, G., Oldenburg, B., Sikkens, M.S.G., Tuyl, S.A. van, Bodegraven, A.A. van, Dutch Workgrp IBD Vulvovaginal Neo, Academic Medical Center, Amsterdam Gastroenterology Endocrinology Metabolism, Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health, Anatomy and neurosciences, Gastroenterology and hepatology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Epidemiology and Data Science, Pathology, AGEM - Digestive immunity, Other Research, AII - Inflammatory diseases, APH - Methodology, Groningen Institute for Organ Transplantation (GIOT), Translational Immunology Groningen (TRIGR), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Gastroenterology & Hepatology
- Subjects
Inflammatory bowel disease ,0302 clinical medicine ,Risk Factors ,Epidemiology ,EPIDEMIOLOGY ,Registries ,INCREASED RISK ,Netherlands ,Vaginal cancer ,education.field_of_study ,Vulvar Neoplasms ,Incidence ,Gastroenterology ,Middle Aged ,CANCER ,PREVALENCE ,THIOPURINES ,Immunosuppressive therapy ,030220 oncology & carcinogenesis ,Cohort ,SURVIVAL ,Female ,030211 gastroenterology & hepatology ,FEMALE GENITAL-TRACT ,Carcinoma in Situ ,Immunosuppressive Agents ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Adult ,medicine.medical_specialty ,Vaginal Neoplasms ,Adolescent ,Population ,Malignancy ,Young Adult ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Internal medicine ,Journal Article ,medicine ,Humans ,COHORT ,Medical history ,education ,Aged ,Retrospective Studies ,Hepatology ,business.industry ,HUMAN-PAPILLOMAVIRUS ,Cancer ,Inflammatory Bowel Diseases ,medicine.disease ,TRENDS ,Vulvar or vaginal malignancy ,Neoplasm Recurrence, Local ,business - Abstract
Immunosuppressive drugs are the cornerstone in the treatment of inflammatory bowel disease (IBD), however they are associated with an increased risk of extra-intestinal cancer. Whether the risk for female genital tract malignancies, including vulvar and vaginal cancer, is increased is less clear.Our aim was to investigate the risk of these malignancies in IBD-patients.Histopathological data of all IBD patients with a vulvar or vaginal (pre-)cancerous lesion were retrieved from the Dutch nationwide network and registry of histopathology and cytopathology from 1991 to 2015. Medical history was retrieved from patient records. Data from the Central Office for Statistics, the Dutch comprehensive cancer organization, and the IBDSL cohort were obtained to calculate the standardized, and age-adjusted incidence rates.Fifty-five patients met the inclusion criteria. A standardized incidence rate of 1.2(95% CI:0.8-1.7) for vulvar and vaginal carcinoma among adult female IBD was calculated, which did not significantly differ from the general population. The use of immunosuppressive therapy did not increase the occurrence of vulvovaginal malignancy, nor did it influence the recurrence rate. However, immunosuppressive drugs ever-users were on average 11 years younger at the time of their gynaecological diagnosis.Overall, our data do not support intensified screening for vulvar or vaginal malignancies in female IBD patients. (C) 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
- Published
- 2020
- Full Text
- View/download PDF